俄鋁(00486.HK)去年鋁產量微升 銷量跌0.5%
俄鋁(00486.HK)公佈,去年第四季鋁產量共95.3萬噸,按季上升1%,其中西伯利亞冶煉廠產量佔鋁總產量93%;鋁銷售量爲98.9萬噸,按季上升8.1%,主要由於第三季的低基數所致;增值產品(VAP)的銷售量爲52.7萬噸,按季升5.9%,佔總銷售量的53%,與第三季度相若。
公司去年鋁產量共376.4萬噸,按年上升0.2%;鋁銷售量按年下降0.5%至總計390.4萬噸;VAP銷售量增長18.1%至203.4萬噸,佔總銷售額52%,相比之下,受新冠肺炎疫情影響,市場波動,2020年該比率爲44%,反映出VAP銷售佔比正在恢復。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.